TREMELIMUMAB, DURVALUMAB
ESR 21-21165
Phase 2 small_molecule active
Quick answer
TREMELIMUMAB, DURVALUMAB for MSS and MSI colorectal and endometrial tumors is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- MSS and MSI colorectal and endometrial tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active